Although there was no significant difference in PFS (p=0.17) between these two groups, Surufatinib combined with ICI and chemo showed a trend towards better survival benefits in the first-line setting.
← all excerpts
The prognostic impact of surufatinib for the treatment of advanced pancreatic ductal adenocarcinoma: a single center real-world retrospective study.
1
—
—